CD44 and breast carcinoma: The metabolic switch to glycolysis was demonstrated in CD44+CD24lowEPCAM+ CSCs in breast cancer, radioresistant CSCs in nasopharyngeal carcinoma, and CD133+CD49f+ CSCs in hepatocellular carcinoma.